A US biopharma company is seeking opportunities addressing rare and/or rare paediatric diseases through late-preclinical and clinical-stage therapeutics. The industry sponsor is a publicly-traded biopharma company based in the United States with deep experience in developing assets for rare diseases. Within its portfolio, the company currently have four late-stage programmes targeting ultra-rare paediatric diseases and rare cancers. The company also has an extensive pipeline of early/preclinical therapies in development for a variety of rare diseases.
Approaches...